QTTB Stock Clocks Best Day In A Year Following Positive Alopecia Data — Analyst Sees Further 200% Upside

• Wells Fargo analyst Derek Archila said the positive data boosts the odds of success for bempikibart.
• Oppenheimer called the data an “overwhelmingly positive derisking event.”
• Mizuho analyst Joseph Catanzaro, meanwhile, lifted the price target to $36 from $14 while keeping an ‘Outperform’ rating.

Shares of Q32 Bio (QTTB) jumped 91% on Monday after the company reported strong 36-week results from the second part of its early-stage trial of bempikibart in patients with severe or very severe alopecia areata.

The stock clocked its best day since July 2025 before slipping 5% after-hours.

Trial Shows Clear Hair Regrowth

Patients treated with bempikibart for 36 weeks saw a 35% average reduction in scalp hair loss severity. In the main group, 40% achieved at least 80% scalp hair coverage. The drug worked in both treatment-naïve patients and those who had previously tried certain drugs belonging to the class of JAK inhibitors. Early follow-up suggested benefits may last after stopping treatment, the company said.

Bempikibart was well tolerated with no serious treatment-related side effects, the company added. The most common issue was mild injection-site reactions.

Wall Street Responds

Following the update, Wells Fargo analyst Derek Archila upgraded Q32 Bio to ‘Overweight’ from ‘Equal Weight’ and raised the price target to $66 from $10. He said the positive data boosts the odds of success for bempikibart and expects the stock to move toward a roughly $2 billion market cap once the company addresses its capital needs.

Oppenheimer raised its price target to $40 from $20 and kept an ‘Outperform’ rating. The firm called the data an “overwhelmingly positive derisking event” that validates the dosing regimen and shows competitive efficacy with approved JAK inhibitors.

Mizuho analyst Joseph Catanzaro, meanwhile, lifted the price target to $36 from $14 while keeping an ‘Outperform’ rating. He highlighted bempikibart’s “JAK-like to better” efficacy and “very favorable” safety profile.

The new price targets imply a potential upside of 68% to 209% from the stock’s closing price on Monday.

Company Announces $200M Offering

Q32 Bio also announced a proposed public offering of $200 million in common stock and pre-funded warrants after-hours. The company plans to use the net proceeds to support the advancement of bempikibart into future clinical trials and for general corporate purposes.

How Did QTTB Retail Traders React?

On Stocktwits, retail sentiment around QTTB stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.

A Stocktwits user said that the stock will crash in light of the $200-million offering announcement.

Another, however, highlighted that the stock didn’t crash too much after-hours despite the offering announcement, and termed it a “great sign.”

QTTB stock has risen over 500% year-to-date. 

Read More: BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use
 

For updates and corrections, email newsroom[at]stocktwits[dot]com.